Skip to main content

A Path Forward for Regenerative Medicine.

Publication ,  Journal Article
Fanaroff, AC; Morrow, V; Krucoff, MW; Seltzer, JH; Perin, EC; Taylor, DA; Miller, LW; Zeiher, AM; Fernández-Avilés, F; Losordo, DW; Henry, TD ...
Published in: Circ Res
August 3, 2018

Although clinical trials of cell-based approaches to cardiovascular disease have yielded some promising results, no cell-based therapy has achieved regulatory approval for a cardiovascular indication. To broadly assess the challenges to regulatory approval and identify strategies to facilitate this goal, the Cardiac Safety Research Consortium sponsored a session during the Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine in September 2017. This session convened leaders in cardiovascular regenerative medicine, including participants from academia, the pharmaceutical industry, the US Food and Drug Administration, and the Cardiac Safety Research Consortium, with particular focus on treatments closest to regulatory approval. A goal of the session was to identify barriers to regulatory approval and potential pathways to overcome them. Barriers identified include manufacturing and therapeutic complexity, difficulties identifying an optimal comparator group, limited industry capacity for funding pivotal clinical trials, and challenges to demonstrating efficacy on clinical end points required for regulatory decisions. Strategies to overcome these barriers include precompetitive development of a cell therapy registry network to enable dual-purposing of clinical data as part of pragmatic clinical trial design, development of standardized terminology for product activity and end points to facilitate this registry, use of innovative statistical methods and quality of life or functional end points to supplement outcomes such as death or heart failure hospitalization and reduce sample size, involvement of patients in determining the research agenda, and use of the Food and Drug Administration's new Regenerative Medicine Advanced Therapy designation to facilitate early discussion with regulatory authorities when planning development pathways.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Res

DOI

EISSN

1524-4571

Publication Date

August 3, 2018

Volume

123

Issue

4

Start / End Page

495 / 505

Location

United States

Related Subject Headings

  • Stem Cell Transplantation
  • Regenerative Medicine
  • Humans
  • Heart Diseases
  • Congresses as Topic
  • Cardiovascular System & Hematology
  • Cardiology
  • Animals
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fanaroff, A. C., Morrow, V., Krucoff, M. W., Seltzer, J. H., Perin, E. C., Taylor, D. A., … Povsic, T. J. (2018). A Path Forward for Regenerative Medicine. Circ Res, 123(4), 495–505. https://doi.org/10.1161/CIRCRESAHA.118.313261
Fanaroff, Alexander C., Valarie Morrow, Mitchell W. Krucoff, Jonathan H. Seltzer, Emerson C. Perin, Doris A. Taylor, Leslie W. Miller, et al. “A Path Forward for Regenerative Medicine.Circ Res 123, no. 4 (August 3, 2018): 495–505. https://doi.org/10.1161/CIRCRESAHA.118.313261.
Fanaroff AC, Morrow V, Krucoff MW, Seltzer JH, Perin EC, Taylor DA, et al. A Path Forward for Regenerative Medicine. Circ Res. 2018 Aug 3;123(4):495–505.
Fanaroff, Alexander C., et al. “A Path Forward for Regenerative Medicine.Circ Res, vol. 123, no. 4, Aug. 2018, pp. 495–505. Pubmed, doi:10.1161/CIRCRESAHA.118.313261.
Fanaroff AC, Morrow V, Krucoff MW, Seltzer JH, Perin EC, Taylor DA, Miller LW, Zeiher AM, Fernández-Avilés F, Losordo DW, Henry TD, Povsic TJ. A Path Forward for Regenerative Medicine. Circ Res. 2018 Aug 3;123(4):495–505.

Published In

Circ Res

DOI

EISSN

1524-4571

Publication Date

August 3, 2018

Volume

123

Issue

4

Start / End Page

495 / 505

Location

United States

Related Subject Headings

  • Stem Cell Transplantation
  • Regenerative Medicine
  • Humans
  • Heart Diseases
  • Congresses as Topic
  • Cardiovascular System & Hematology
  • Cardiology
  • Animals
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology